SCHEMBL332630

SCHEMBL332630

c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 1.00
CYP11B2 P19099 3/20 1.00
CYP19A1 P11511 12/20 0.70
NR1I2 O75469 2/20 0.70
ADORA3 P0DMS8 2/20 0.70
TBXA2R P21731 2/20 0.70
CCKBR P32239 2/20 0.70
OPRK1 P41145 2/20 0.70
SLC6A3 Q01959 2/20 0.70
KCNH2 Q12809 2/20 0.70
NR1H4 Q96RI1 2/20 0.70
CYP3A4 P08684 2/20 0.70
MEN1 O00255 1/20 0.70
SLC22A1 O15245 1/20 0.70
KCNN4 O15554 1/20 0.70
GMNN O75496 1/20 0.70
USP2 O75604 1/20 0.70
TRPM2 O94759 1/20 0.70
ABCB11 O95342 1/20 0.70
EGFR P00533 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL27766624 0.94 CYP11B1 (0.89) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
Formaldehyde SCHEMBL27502810 0.94 CYP11B1 (0.89) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL12199510 0.94 CYP11B1 (0.89) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL5738206 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL3827048 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL7156136 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL1484197 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL11683608 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL5320974 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL5437850 0.89 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4321541-B1 RESIN COMPOSITION, RESIN SHEET, MULTILAYER PRINTED WIRING BOARD AND SEMICONDUCTOR DEVICE MITSUBISHI GAS CHEMICAL CO (JP) 2025-08-06 EP claimed
CN-119215982-A Catalyst for co-production of dimethyl carbonate and monomethyl malonate, and preparation method and application thereof 中国石油化工股份有限公司 2024-12-31 CN claimed
CN-119186651-A Catalyst for preparing dialkyl carbonate and preparation method and application thereof 中国石油化工股份有限公司 2024-12-27 CN claimed
WO-2024261723-A1 RHENIUM COMPLEXES COMPRISING A LIGAND WITH A DISTAL INVERTED TRIGONAL PYRAMIDAL STRUCTURAL MOTIF AND USE THEROF UNIVERSIDADE NOVA DE LISBOA (PT) 2024-12-26 WO claimed
CN-119002179-A Photosensitive resin composition, dry film resist, photosensitive laminate, resist pattern, and semiconductor package carrier 杭州福斯特电子材料有限公司 2024-11-22 CN claimed
CN-118685213-A New energy alcohol-based fuel formula for replacing traditional diesel 邢台顺和生物科技有限公司 2024-09-24 CN claimed
CN-117624919-B Cold-mixing cold-paving vegetable oil-based epoxy asphalt and preparation method thereof 北京建筑大学 2024-08-13 CN claimed
CN-115572371-B Preparation method of ionic porous polymer material and application of essential oil in adsorption and diterpene removal 杭州师范大学 2024-06-25 CN claimed
CN-117956814-A Perovskite solar cell and preparation method thereof 晶澳(扬州)太阳能科技有限公司 2024-04-30 CN claimed
CN-117624919-A Cold-mixing cold-paving vegetable oil-based epoxy asphalt and preparation method thereof 北京建筑大学 2024-03-01 CN claimed
WO-2002089779-A2 COMBINED PREPARATION FOR THE PROPHYLAXIS AND/OR THERAPY OF NERVE CELL AND/OR GLIA CELL DAMAGE USING A NOVEL METHOD OF TREATMENT MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) 2002-11-14 WO claimed
US-20020065259-A1 Glucocorticoid blocking agents for increasing blood-brain barrier permeability BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) 2002-05-30 US claimed
WO-2002040018-A1 TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION ALCON, INC. (CH) 2002-05-23 WO claimed
EP-1047410-A1 TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS ALCON LABORATORIES, INC. (US) 2000-11-02 EP claimed
US-6051573-A Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists ALCON LABORATORIES, INC. (US) 2000-04-18 US claimed
WO-1999032101-A1 TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS ALCON LABORATORIES, INC. (US) 1999-07-01 WO claimed
US-4500540-A DIETETICS HOFFMANN-LA ROCHE INC. (US) 1985-02-19 US claimed
EP-0010565-B1 PROCESS FOR PREPARING N-TRITYLIMIDAZOLE COMPOUNDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1982-11-10 EP claimed
US-4216333-A Process for preparing N-tritylimidazole compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-08-05 US claimed
EP-0010565-A1 Process for preparing N-tritylimidazole compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-05-14 EP claimed